Industry: Health care Region: Austria Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
An Austrian company, founded in 1996, is an international team composed of more than 600 experts from more than 20 countries. Committed to developing innovative solutions to solve unmet medical needs, especially in the fields of rare diseases and intensive care medicine. The company focuses on developing, producing and selling innovative solutions in the fields of hematology oncology, cardiology, pulmonary diseases and intensive care. Its export quota is as high as 80%, and it has strong competitiveness and influence in the international market.
Solution introduction:
As a comprehensive pharmaceutical company, the company invests most of its turnover in the research and development of new drugs every year to ensure that it can continuously provide innovative medical solutions. The company has a wide range of business, covering research and development, drug production, marketing and sales. The company covers all aspects of product development, from preclinical research and toxicology to pharmaceutical and clinical development, ensuring that every link meets high standards. In addition, the company is also involved in the fields of regulatory affairs, quality management and pharmacovigilance to ensure that its products meet international standards in terms of safety, effectiveness and compliance. Through this comprehensive and rigorous R&D and production process, the company can provide high-quality innovative drugs to patients around the world and improve their health and quality of life.
Cooperation mode:
To seek China's partners in the field of rare diseases and intensive care medicine.